Serina Therapeutics, Inc. Increase (Decrease) in Insurance Liabilities
Serina Therapeutics, Inc. (SER) reported Increase (Decrease) in Insurance Liabilities of -$1.07 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-22.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInsuranceLiabilities · last filed 2024-03-22
- Serina Therapeutics, Inc. increase (decrease) in insurance liabilities for the quarter ending 2023-12-31 was $0.00.
- Serina Therapeutics, Inc. increase (decrease) in insurance liabilities for the quarter ending 2023-09-30 was -$364.00K.
- Serina Therapeutics, Inc. increase (decrease) in insurance liabilities for the quarter ending 2023-06-30 was -$358.00K.
- Serina Therapeutics, Inc. increase (decrease) in insurance liabilities for the quarter ending 2023-03-31 was -$353.00K.
- Serina Therapeutics, Inc. increase (decrease) in insurance liabilities for fiscal 2023 was -$1.07M.
- Serina Therapeutics, Inc. increase (decrease) in insurance liabilities for fiscal 2022 was -$983.00K.
- Serina Therapeutics, Inc. increase (decrease) in insurance liabilities for fiscal 2021 was -$921.00K.
- Serina Therapeutics, Inc. increase (decrease) in insurance liabilities for fiscal 2020 was -$713.00K.
| Period end | Increase (Decrease) in Insurance Liabilities 3 month | Increase (Decrease) in Insurance Liabilities 6 month | Increase (Decrease) in Insurance Liabilities 9 month | Increase (Decrease) in Insurance Liabilities 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | -$364.00K derived: sum of 2 quarters · filed 2024-03-22 | -$722.00K derived: sum of 3 quarters · filed 2024-03-22 | -$1.07M 10-K · filed 2024-03-22 |
| 2023-09-30 | -$364.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$722.00K derived: sum of 2 quarters · filed 2023-11-14 | -$1.07M 10-Q · filed 2023-11-14 | -$1.07M derived: sum of 4 quarters · filed 2024-03-22 |
| 2023-06-30 | -$358.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$711.00K 10-Q · filed 2023-08-14 | -$711.00K derived: sum of 3 quarters · filed 2024-03-22 | -$1.04M derived: sum of 4 quarters · filed 2024-03-22 |
| 2023-03-31 | -$353.00K 10-Q · filed 2023-05-12 | -$353.00K derived: sum of 2 quarters · filed 2024-03-22 | -$683.00K derived: sum of 3 quarters · filed 2024-03-22 | -$1.01M derived: sum of 4 quarters · filed 2024-03-22 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | -$330.00K derived: sum of 2 quarters · filed 2024-03-22 | -$658.00K derived: sum of 3 quarters · filed 2024-03-22 | -$983.00K 10-K · filed 2024-03-22 |
| 2022-09-30 | -$330.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$658.00K derived: sum of 2 quarters · filed 2023-11-14 | -$983.00K 10-Q · filed 2023-11-14 | -$983.00K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$328.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$653.00K 10-Q · filed 2023-08-14 | -$653.00K derived: sum of 3 quarters · filed 2023-08-14 | -$963.00K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$325.00K 10-Q · filed 2023-05-12 | -$325.00K derived: sum of 2 quarters · filed 2023-05-12 | -$635.00K derived: sum of 3 quarters · filed 2023-05-12 | -$942.00K derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$310.00K derived: sum of 2 quarters · filed 2023-03-31 | -$617.00K derived: sum of 3 quarters · filed 2023-03-31 | -$921.00K 10-K · filed 2023-03-31 |
| 2021-09-30 | -$310.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$617.00K derived: sum of 2 quarters · filed 2022-11-10 | -$921.00K 10-Q · filed 2022-11-10 | -$921.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$307.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | -$611.00K 10-Q · filed 2022-08-12 | -$611.00K derived: sum of 3 quarters · filed 2022-08-12 | -$851.00K derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | -$304.00K 10-Q · filed 2022-05-13 | -$304.00K derived: sum of 2 quarters · filed 2022-05-13 | -$544.00K derived: sum of 3 quarters · filed 2022-05-13 | -$703.00K derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | -$240.00K derived: sum of 2 quarters · filed 2022-03-29 | -$399.00K derived: sum of 3 quarters · filed 2022-03-29 | -$713.00K 10-K · filed 2022-03-29 |
| 2020-09-30 | -$240.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$399.00K derived: sum of 2 quarters · filed 2021-11-12 | -$713.00K 10-Q · filed 2021-11-12 | -$712.00K derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | -$159.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | -$473.00K 10-Q · filed 2021-08-13 | -$472.00K derived: sum of 3 quarters · filed 2021-08-13 | -$624.00K derived: sum of 4 quarters · filed 2021-08-13 |
| 2020-03-31 | -$314.00K 10-Q · filed 2021-05-17 | -$313.00K derived: sum of 2 quarters · filed 2021-05-17 | -$465.00K derived: sum of 3 quarters · filed 2021-05-17 | |
| 2019-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | -$151.00K derived: sum of 2 quarters · filed 2021-03-31 | -$599.00K 10-K · filed 2021-03-31 | |
| 2019-09-30 | -$152.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | -$600.00K 10-Q · filed 2020-11-16 | ||
| 2019-06-30 | -$448.00K 10-Q · filed 2020-08-14 | |||
| 2018-12-31 | -$74.00K 10-K/A · filed 2020-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |